Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Critical Outcome Technologies Inc V.COT

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  COTQF

Critical Outcome Technologies Inc is a biotechnology company. The Company is engaged in applying its proprietary computer-based technology, CHEMSAS, to identify and optimize drug candidates at early stage of preclinical drug development.
Price: $0.26 | Change: $-0.025 | %Change: -8.77%
Volume: 137,056 | Day High/Low: 0.29/0.26 | 52 Week High/Low: 0.365/0.12
View modes: 
0 stars

COTI-2 in Treating Head and Neck Cancers

looks like more good news and progress........ Critical Outcome Technologies and MD Anderson Cancer Center to Evaluate COTI-2 in Treating Head and Neck Cancers Initial results suggest that COTI-2...read more
0 stars

RE:no difference

be great to have a US listing but I think they have been getting their profile raised in the US lately... new investors etc.   Hopefullly can keep making progress on that.  rate and reply
0 stars

Present at 13th Annual BIO Investor Forum on Tuesday

Critical Outcome Technologies to Present at 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 Significant Impact of COTI-2's p53-dependent Mechanism of Action on Cancer to Be Highlighted...read more
0 stars

no difference

we have to move away from canadian markets go usa or anywhere but canada we spin are wheels at best at worst we go down  rate and reply
0 stars

COTI-2, Receives Sixth U.S. Patent and First Japanese Patent

Critical Outcome's Lead Cancer Drug Candidate, COTI-2, Receives Sixth U.S. Patent and First Japanese Patent Additional Patents Further Enhance the Value of COTI-2 Friday, October 03, 2014...read more
1 star

RE:RE:Key commercialization initiatives advanced during fiscal2014

  rate and reply
0 stars

COTI-2: Potent Anti-Cancer P53-Dependent Activity

Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2 Company Completes Definitive Experiments With Its Lead Cancer Drug Wednesday, September 10, 2014 ...read more
0 stars

NEWS - Letter of Intent for Phase 1 Development of COTI-2...

Critical Outcome Technologies and UT MD Anderson Cancer Center Sign Letter of Intent for Phase 1 Development of COTI-2 Monday, September 08, 2014   Critical Outcome Technologies and UT MD...read more
0 stars

RE:Key commercialization initiatives advanced during fiscal2014

hi Rob, I've read the SeeThru Research. I find CHEMSAS interesting and think it may could have lot of potential for Pharma companies, but I can't -aaalready- see special events/trigger on the horizon...read more
0 stars

Key commercialization initiatives advanced during fiscal2014

Critical Outcome Technologies Reports Year-End Financial and Operating Results Key commercialization initiatives advanced during fiscal 2014 Thursday, July 24, 2014   Critical Outcome...read more
0 stars

some news

http://www.stockhouse.com/news/press-releases/2014/07/16/critical-outcome-technologies-inc-announces-warrant-term-amendment  rate and reply
0 stars

no news

nothing, zip, nada, not even a hint of what may or may not have happened in san diago.  rate and reply
0 stars

cibc attempting to sell also

about 810,000 shares from .32  to .35 cents.  does anyone know why?  is there news to come soon?  rate and reply
0 stars

almost 300,00 shares exchanged today

with BMO selling  or attempting to sell over 125,000 shares, anyone know why?  price dropped .4 cents to .24  rate and reply
0 stars

san diego

I wonder what;s going on there?  rate and reply
0 stars

RE:Personalized Cancer Care With Project ROSALIND

yep and  I like this statement : " and are talking with a number of potential partners about commercial validation opportunities," added Dr. Danter.  rate and reply
0 stars

Personalized Cancer Care With Project ROSALIND

Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALIND ROSALIND, a patent-pending cancer cell simulation, will be introduced at the upcoming BIO International...read more
1 star

RE:NEWS!! COT Receives Orphan Drug Designation For COTI-2

So we jumped 50% just ahead of the news? Either someone had high hopes or someone has a big mouth lol. Very interesting story though. * Always conduct your own due diligence when investing and...read more
0 stars

NEWS!! COT Receives Orphan Drug Designation For COTI-2

Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2 Designation for treatment of ovarian cancer provides further support for the clinical development of COTI-2 Tuesday, June...read more
0 stars

RE:RE:great volume today

wow, just hit 29 , days after the big volume days cleaning up supply around 19-23 cents...   if we can close over 28 this week that will be over the Feb highs and indicate a new leg higher possibly...read more

How to invest in private equity without writing a $1 million check.

Click here to watch the video